other uses Taxobox status name Lynx ref name msw3 image Lynxlynx poing.jpg image caption Eurasian LynxLynxlynx regnum Animal ia phylum Chordate Chordata classis Mammal ia ordo Carnivora familia Felidae subfamilia Felinae genus Lynx genus authority Robert Kerr writer Kerr , 1792 type species Eurasian LynxLynxlynx type species authority Carolus Linnaeus Linnaeus , 1758 subdivision ranks Species subdivision Lynxlynx br Lynx canadensis br Lynx pardinus br Lynx rufus range map Lynx range.png range map caption The overall range of Lynx species. A lynx IPAc en icon l k s ref name OxfordDic plural lynx or lynxes ref name Longman is any of the four Lynx genus species of medium sized wildcats. The name lynx originated in Middle English via Latin from Greek word lunx , ref name OxfordDic derived ... of the genus Felis . The caracal , despite sometimes being called Persian lynx or African lynx , does not belong to this genus. Appearance Image Lynx lynx2.jpg thumb left The Eurasian lynxLynxlynxLynx .... All species of lynx also have white fur on their chests, bellies and on the insides of their legs, which are extensions of the chest and belly fur. Also, the lynx s colouring, fur height and paw ... haired, dark and the paws are smaller and less padded as the lynx ranges to its colder northern climates ... hand or foot. The smallest species are the bobcat and the Canada lynx , while the largest is the Eurasian lynx , however there are considerable variations within species. class wikitable Physical characteristics of Lynx species Species Weight Length Height standing at shoulders Eurasian Lynx convert 18 to 30 kg lb males br convert 18 kg lb females convert 81 to 129 cm in convert 70 cm in ref name Jackson Ref applies to all three Canada Lynx convert 8 to 11 kg lb convert 80 to 105 cm in convert 48 to 56 cm in ref name dnr Ref applies to all three Iberian Lynx convert 12.9 ... name utd convert 51 to 61 cm in abbr off ref name cah Species The four living species of the Lynx genus ... more details
Italic title infobox journal title Pharmacology & Therapeutics abbreviation Pharmacol. Ther. discipline Pharmacology frequency Monthly history 1976 present publisher Elsevier editor S.J. Enna ISSN 0163 7258 eISSN 1879 016X CODEN PHTHDT OCLC 04981366 website http www.elsevier.com wps find journaldescription.cws home 525486 description description link1 http sciencedirect.com science journal 01637258 link1 name Online access impact 8.897 impact year 2009 openaccess optional Pharmacology & Therapeutics is a medical journal medical review journal published by Elsevier . It incorporates Pharmacology & Therapeutics. Part A Chemotherapy, Toxicology and Metabolic Inhibitors and Pharmacology & Therapeutics. Part B General and Systematic Pharmacology , both originally published by Oxford University Press . External links Official http www.elsevier.com wps find journaldescription.cws home 525486 description description med journal stub Category Pharmacology journals Category Elsevier academic journals Category Publications established in 1976 Category English language journals Category Monthly journals fr Pharmacology & Therapeutics ... more details
Unreferenced date September 2008 Infobox Company company name Halozyme Therapeutics logo Image Halozyme Therapeutics Logo.gif company type Public company Public nasdaq HALO company slogan foundation 1998 location San Diego, California , United States USA key people Jonathan E. Lim , President & CEO num employees 130 industry Biopharmaceutical products Biologic s revenue profit 3,799,521 United States dollar USD 2007 homepage http www.Halozyme.com www.halozyme.com Halozyme Therapeutics , based in San Diego, California , is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology , oncology , dermatology and drug delivery markets. http www.halozyme.com Category Companies in the NASDAQ Biotechnology Index Category Companies based in San Diego, California ... more details
Image Opexa.jpg right Opexa Therapeutics corporate logo Opexa Therapeutics nasdaq OPXA , formerly known as PharmaFrontiers , is a biotechnology company that develops autologous cellular therapies for the treatment of multiple sclerosis , congestive heart failure , and diabetes . The company is focused on autologous cellular therapy applications based on its proprietary stem cell and T cell vaccination technologies. Key products and research include Tovaxin A T cell therapeutic vaccine for multiple sclerosis Heart Cardiac stem cell therapy Diabetes mellitus Diabetes stem cell therapy Location Opexa Therapeutics is located in The Woodlands, Texas The Woodlands , Texas convert 30 mi km north of Houston , Texas . The company has a convert 10200 sqft m2 abbr on facility on convert 3 acre m2 in The Woodlands, Texas The Woodlands . This location provides space for pipeline development through R & D a specialized Flow cytometry and Microscopy lab support of clinical trials with Good manufacturing practice GMP manufacturing Suites Quality Systems management with Quality Control Laboratory, Regulatory Affairs, Quality Assurance as well as administrative support space. External links http www.opexatherapeutics.com Opexa Therapeutics webpage http news.bbc.co.uk 1 hi health 4787430.stm BBC Article 3 8 06 http www.upi.com HealthBusiness view.php?StoryID 20060309 042811 3384r UPI Health Brief Category Companies based in Texas Category Biotechnology companies Category Vaccination related organizations ... more details
Sirna Therapeutics was a San Francisco , California based biotechnology company that explores the use of RNA interference in human disease therapy. Sirna s development pipeline includes several small interfering RNA siRNA drug s, thought to stably gene silencing silence the gene expression expression of specific disease related genes. Sirna s clinical trial of an siRNA based treatment for age related macular degeneration is the first such trial for an siRNA drug. ref name Sirna cite web url http www.sirna.com wt page ocular title Ocular Therapeutic Pipeline accessdate 2007 02 12 archiveurl http web.archive.org web 20070127073635 http www.sirna.com wt page ocular Bot retrieved archive archivedate 2007 01 27 ref ref name Sah Sah D 2006 . Therapeutic potential of RNA interference for neurological disorders . Life Sci 79 19 1773 80. DOI 10.1016 j.lfs.2006.06.011 PMID 16815477 ref Sirna Therapeutics was acquired by Merck & Co. in 2006 in a deal worth 1.1 billion. ref name Merck http www.merck.com newsroom press releases corporate 2006 1030.html Merck & Co., Inc. Announces Completion of Acquisition of Sirna Therapeutics, Inc. ref References reflist External links http www.sirna.com Sirna Therapeutics Category Companies based in San Francisco, California Category Merck US corp stub ... more details
Use mdy dates date September 2010 Infobox company name Acorda Therapeutics Inc. logo caption type Public company Public nasdaq ACOR , FWB CDG genre fate predecessor successor foundation Start date 1995 ref name Acorda FAQ http phx.corporate ir.net phoenix.zhtml?c 194451&p irol faq Acorda FAQ ref founder Ron Cohen defunct location city Hawthorne, New York location country United States location locations area served key people Ron Cohen br Andrew R. Blight industry Health care br Biotechnology products Tizanidine Zanaflex br 4 Aminopyridine Ampyra production services revenue profit United States Dollar US 54.7 Million small FY 2009 small ref name 09IncomeStatement wikinvest stock Acorda Therapeutics ACOR Data Income Statement Acorda Therapeutics ACOR annual SEC income statement filing via Wikinvest ref operating income loss United States Dollar US 79.5 Million small FY 2009 small ref name 09IncomeStatement net income loss United States Dollar US 83.9 Million small FY 2009 small ref name 09IncomeStatement assets increase United States dollar US 319 Million small FY 2009 small ref name 09BalanceSheet wikinvest stock Acorda Therapeutics ACOR Data Balance Sheet Acorda Therapeutics ACOR annual SEC balance sheet filing via Wikinvest ref equity decrease United States dollar US 137 Million small FY 2009 small ref name 09BalanceSheet owner num employees 220 ref name Acorda FAQ parent divisions subsid homepage http www.acorda.com Acorda.com footnotes intl Acorda Therapeutics nasdaq ACOR , FWB CDG is a biotechnology company based in Hawthorne, New York . Acorda Therapeutics develops drugs to improve therapies that improve neurological function in people with multiple sclerosis , spinal ... As of 2008 12 31 df US the members of the board of directors of Acorda Therapeutics are ref http phx.corporate ... companies acorda therapeutics inc index.html Acorda Therapeutics Inc. The New York Times http www.hoovers.com global cobrands nasdaq factsheet.xhtml?ID 121830 Acorda Therapeutics Inc. Hoover s Pharmaceutical ... more details
Unreferenced date May 2010 ARYx Therapeutics, Inc. nasdaq ARYX is an United States American bio pharmaceutical company, headquartered in Fremont, California , focused on developing a portfolio of internally discovered product candidates. The company uses its RetroMetabolic Drug Design technology to design molecules that retain the efficacy of original and well established drugs but which are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these original compounds. References Reflist External links http www.aryx.com Official website Pharmaceutical companies of the United States DEFAULTSORT Aryx Therapeutics, Inc. Category Pharmaceutical companies of the United States ... more details
Infobox Company name TauRx Therapeutics logo type Public company Public genre foundation Singapore 2002 founder Professor Claude Wischik br Dr K. M. Seng location city location country location Singapore locations area served key people Professor Claude Wischik, small Executive Chairman small br Dr Shay Way Seng, small Managing Director small br John Harry, small Lead Pharmaceutical Strategist small industry Medication Pharmaceuticals products services market cap revenue operating income net income assets equity owner num employees parent divisions subsid homepage http www.taurx.com TauRx Therapeutics footnotes intl yes TauRx Therapeutics Ltd is a startup pharmaceutical company that is based in Singapore . ref cite web last Marchione first Marilynn title Experimental Alzheimer s drug shows early promise publisher Associated Press date 2008 07 30 url http ap.google.com article ALeqM5jK3o2IH 4QHTz4i5e9OlzzFCA2pgD927P6QO0 accessdate 2008 07 31 ref The company was founded in 2002 by the late gynecologist , surgeon and venture capitalist K. M. Seng and the research biologist Claude Wischik who is currently its CEO. In 1988 Wischik and coworkers discovered that abnormal fibres of tau protein form inside nerve cells in patients with Alzheimer disease , and that their aggregation correlatates to the development of dementia . The company has focused on the development of drugs that dissolve tau fibres in an attempt to manage patients with Alzheimer. rember is an investigational drug for this purpose by TauRx Therapeutics. ref cite web last Wilkinson first Emma title Alzheimer s drug halts decline publisher BBC date 2006 07 29 url http news.bbc.co.uk 2 hi health 7525115.stm BBC news accessdate 2008 07 29 ref References references External links http www.taurx.com Official site Category Pharmaceutical companies Category Companies of Singapore ... more details
infobox company name Opsona Therapeutics logo Image Opsona Therapeutics logo 200x73.jpg 200px Opsona Therapeutics is a drug development company specialising in the human immune system and new drugs and vaccines to prevent and treat autoimmune Inflammation inflammatory conditions, cancer s and infectious disease s. ref http www.irishtimes.com newspaper innovation 2009 0302 1224241917142.html Article in the Irish Times ref ref http www.sbpost.ie post pages p story.aspx qqqt People In Business qqqm nav qqqid 39708 qqqx 1.asp Sunday Business Post article ref ref http investing.businessweek.com research stocks private snapshot.asp?privcapId 20741516 BusinessWeek company profile ref Based in Ireland , Opsona is a spin out from Trinity College Dublin TCD ref http www.irishtimes.com newspaper finance 2008 0623 1214047001272.html Article in the Irish Times ref . Ireland is ranked highly in the world in immunology research, and TCD has been at the forefront of the field ref http www.topuniversities.com worlduniversityrankings results 2007 overall rankings top 100 universities Times Higher Educational Supplement QS World University Rankings 2007 ref . Opsona s research is primarily focused on the role of Toll like receptors TLRs and TLR signalling in human innate immunity . The company was founded in 2004 by three immunologists Professor Luke O Neill ref http www.irishexaminer.ie ireland trinity team makes vaccine discovery 90894.html Article in the Irish Examiner ref Professor Kingston Mills ref http www.tcd.ie Biochemistry research k mills.php Article on the Trinity College Dublin website ref Professor Dermot Kelleher ref http www.tcd.ie Communications news news.php?headerID 1108&vs date 2009 2 1 Article on the Trinity College Dublin website ref Opsona s main investors are international and life science focused Inventages Venture Capital Bahamas ref http www.fiercebiotech.com press releases opsona therapeutics closes eur18m funding 0 Article on Fierce Biotech ref Seroba Bioventures ... more details
Infobox Company name Proteon Therapeutics company logo Image Proteon therapeutics logo.JPG 249px Proteon Therapeutics type Privately held company Private foundation industry Pharmaceuticals homepage http www.proteontherapeutics.com www.proteontherapeutics.com Proteon Therapeutics, Inc. is a developer of pharmaceuticals with offices in Waltham, Massachusetts Waltham , Massachusetts and Kansas City, Missouri Kansas City , Missouri . It is developing PRT 201, a drug to improve blood flow following vascular surgery procedures, and, more broadly, is interested in vascular access for hemodialysis and peripheral arterial disease PAD . On September 10, 2008, Proteon announced that the Food and Drug Administration had granted fast track status to PRT 201. Proteon was founded by Dr. F. Nicholas Franano based on technology created at Johns Hopkins University . Major investors in the company include MPM Capital , Rockhill Partners , TVM Capital , Skyline Ventures , Prism VentureWorks , Vectis Life Sciences and Intersouth Partners . They have invested over 72 million in the company. ref cite news first Rob last Roberts authorlink coauthors title Proteon secures 12M in financing url http www.bizjournals.com kansascity stories 2007 04 02 daily30.html work Kansas City Business Journal publisher date April 5, 2007 accessdate 2008 07 27 ref On March 5, 2009, the company announced that it had raised 32 million from its existing investors plus MPM Capital and Vectis Life Sciences. Proteon also announced that it had entered into an option agreement to be acquired by Novartis for up to 550 million. ref cite news url http www.boston.com business ticker 2009 03 proteon raises.html work The Boston Globe title Proteon raises 38m, signs option deal with Novartis date March 5, 2009 ref References Reflist cite news first Rob last Roberts authorlink coauthors title Proteon secures 12M in financing ... Proteon Therapeutics, Inc. Pharmaceutical companies of the United States Category Pharmaceutical ... more details
Infobox Company company name Prime Therapeutics company logo company type Limited Liability Corporation foundation 1998, created by a merger location Eagan, Minnesota key people Eric Elliott, CEO industry Pharmacy Benefit Management revenue N A operating income N A net income N A num employees 1,850 parent Health Care Service Corporation , Blue Cross and Blue Shield of Alabama , Blue Cross and Blue Shield of Minnesota , Blue Cross and Blue Shield of Nebraska , Blue Cross and Blue Shield of Kansas , Blue Cross Blue Shield of North Dakota , Blue Cross and Blue Shield of Florida , Blue Cross Blue Shield of Wyoming and Blue Cross and Blue Shield of Montana subsid PrimeMail Pharmacy homepage www.PrimeTherapeutics.com, www.MyPrime.com, www.MyPrimeMail.com footnotes N A Prime Therapeutics LLC is a Pharmacy Benefit Manager PBM headquartered in Eagan, Minnesota . The company is privately held by organizations representing 12 Blue Cross and Blue Shield BCBS plans in Alabama, Florida, Illinois, Kansas, Minnesota, Montana, Nebraska, New Mexico, North Dakota, Oklahoma, Texas and Wyoming. Prime Therapeutics operates contact centers in Omaha, Nebraska and Irving, Texas and operates two mail service pharmacies in Irving, Texas , and Albuquerque, New Mexico . The company also has offices in Chicago , Jacksonville, Florida , Alabama and Washington, D.C. examplefarm Prime Therapeutics is the largest privately held PBM in the United States whose stakeholders are Health Care Service Corporation , Blue Cross and Blue Shield of Alabama , Blue Cross and Blue Shield of Minnesota , Blue Cross and Blue Shield of Nebraska , Blue Cross and Blue Shield of Kansas , Blue Cross Blue Shield of North Dakota , Blue Cross and Blue Shield of Florida , Blue Cross Blue Shield of Wyoming and Blue Cross and Blue ... and First Plan of Minnesota. Prime Therapeutics was created by the consolidation of Pharmacy Gold ... Pharmacy Gold or Goldnet, and BCBS Nebraska as Propar. Prime Therapeutics is the largest privately ... more details
Insert Therapeutics , Inc., now Calando Pharmaceuticals, Inc., is a medical research company that uses nanobiotechnology specializing in therapeutic agents that are conjugation chemistry conjugate d, to facilitate and enhance drug delivery . The small company was founded in 2000, is located in Pasadena, California , and majority owned by Arrowhead Research Corporation . The conjugates consist of a cyclodextrin containing polymer Cyclosert that acts as a drug delivery system, and a linked medication, such as a chemotherapeutic drug of already proven efficacy. ref name IT 101 http clinicaltrials.gov ct show NCT00333502?order 1 IT 101 trial ref The size of the polymer is designed to fit the specific target, as vessels in a neoplasm allow for leakage of different size of polymers, as in healthy tissue. The leaked conjugates are concentrated in the target area. As a result chemotherapeutic activity is locally enhanced, while general side effects are decreased. ref name IT 101 At least one of their conjugates, IT 101 , has been investigated in a clinical trial at City of Hope National Medical Center . ref name IT 101 References references External links http www.calandopharma.com Calando Pharmaceuticals, Inc. was Insert Therapeutics, Inc. http www.ceruleanrx.com Cerulean Pharma, Inc. IT 101 licensee Category Biotechnology ar ... more details
Orphan date February 2009 Unreferenced date February 2007 Pharmacy and Therapeutics is a committee at a hospital or an insurance plan that meets to decide which drugs will appear on that entity s drug formulary. The committee usually consists of both doctors and pharmacists. They must weigh the costs and benefits of each drug and decide which ones provide the most efficacy per dollar. Most generic drugs are available on formularies, except in cases where that class of drugs are no longer considered safe and efficacious. For instance most formularies will not cover barbiturates since their therapeutic index is low compared to benzodiazepines . Barbiturates have a danger of overdosing that occurs at a smaller milligram range than the benzodiazepines. Category Hospitals Pharma stub ... more details
Orphan date February 2009 Ortek Therapeutics, Inc. is a private pharmaceutical company based in Roslyn Heights, New York which specializes in researching and producing caries prevention products. It was founded in 1998. Their most notable product is Cavistat, which is used in their sugarless BasicMints. Cavistat contains arginine bicarbonate and calcium bicarbonate. The arginine is broken down by bacteria which produce acid neutralizing alkali, and the bicarbonate aid in buffering the teeth from acid. The product was licensed to the company by The Research Foundation of the State University of New York after being developed by Department of Oral Biology and Pathology at Stony Brook University. A 2008 clinical trial published in the Journal of Clinical Dentistry found that BasicMints were highly effective in preventing caries in Venezuelan children, as those consuming the mints had 62 less cavities than the placebo group. ref http www.dentistry.co.uk news news detail.php?id 1160 Experimental chewy mint beats tooth decay ref Other products include DenClude, ProClude, and SensiStat. These are generally available only through a dental office. ref http www.dentalofficemag.com display article 216389 55 none none Onlin Ortek Therapeutics announces new dental cream for sensitive teet Ortek Therapeutics announces new dental cream for sensitive teeth ref BasicMints are not yet approved for consumption in the United States, and the company is planning to submit an FDA application in 2008. ref http www.reuters.com article pressRelease idUS126983 08 Apr 2008 PRN20080408 Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints ref The company is optimistic as to its prospects after the trial, and is retaining Piper Jaffray Piper Jaffray & Co. to help evaluate its business options. ref http www.forbes.com businesswire feeds businesswire 2008 06 11 businesswire20080611005919r1.html Ortek Retains Piper Jaffray & Co. to Evaluate Strategic Options For Cavity Fighting ... more details
Infobox Company company name IL Therapeutics Inc. company type foundation location 105E 111 Research Drive, Saskatoon, Saskatchewan Saskatoon , Saskatchewan SK , Canada key people industry Biotechnology num employees products homepage IL Therapeutics Inc. was previously owned by Western Life Sciences Venture Fund LP Western Life Sciences and in 2006 its shares were purchased by Pacgen Biopharmaceuticals Corporation Pacgen ref name pac Citation last Pacgen Biopharmaceuticals Corporation first author link last2 first2 author2 link title Pacgen Biopharmaceuticals Acquires IL Therapeutics Inc. date year url http www.pacgenbiopharm.com investor pdfs news release20060412.pdf accessdate Sept 9, 2007 ref History Saskatchewan Research Council operates a bio processing laboratory which facilitated biomedical research. IL Therapeutics was developed from research first begun at the Western College of Veterinary Medicine Pharmaceuticals Currently IL Therapeutics is working on a drug candidate, IL 8 3 73 K11R G31P PAC G31P for relief of Acute Respiratory Distress Syndrome ARDS ref name pac3 Citation last Pacgen Biopharmaceuticals Corporation first author link last2 first2 author2 link title Pacgen Biopharmaceuticals Acquires IL Therapeutics Inc. date year url http www.pacgenbiopharm.com investor releases 20060412.html accessdate Sept 9, 2007 ref The Saskatchewan Research council, SRC also assisted with the funding of this project through the Agriculture Development Fund SRC Industry Venture Fund. ref name src Citation last Saskatchewan Research Council 2005 2006 Annual Report first author link last2 first2 author2 link title Sustainable Science Solutions date year url http www.src.sk.ca store account download file.cfm?productID 3483&freeDownloadID 538 accessdate Sept 9, 2007 ref The successful progression of G31PRecently the University of Saskatchewan Industry Liaison Office ILO decided to commercialize a commercialize this new drug treatment. ref name UofS Citation last U of S News ... more details
Cynapsus Therapeutics Inc. TSXV CTH is a specialty clinical development pharmaceutical company targeting diseases of the brain. Based in Toronto , Canada . Formerly named Cannasat Therapeutics they changed their name to Cynapsus Therapeutics in 2010. ref http www.marketwire.com press release Cannasat Changes Name to Cynapsus Therapeutics TSX VENTURE CTH 1148145.htm ref Company Overview Cynapsus is a specialty clinical development pharmaceutical company targeting diseases of the brain. Cynapsus has a lower risk Parkinson s drug candidate, which is a reformulation of an approved drug that can address a moderate to severe patient population. Cynapsus also has a proprietary formulation technology for cannabinoid drug candidates, which may be used to treat neuropathic pain associated with multiple sclerosis and cancer, as well as for nausea vomiting and appetite stimulation. Cynapsus s strategy is to grow its portfolio of drug candidates through in licensing and acquisitions, and to advance projects to Phase 2 proof of concept clinical studies. Once the drug candidates are sufficiently derisked, Cynapsus intends to out license the programs to the appropriate Pharma marketing partners for a combination of upfront, milestone, and royalty payments. Products RELIVAR Relivar, a buccal tablet for symptomatic management of neuropathic pain, contains the active ingredient, dronabinol or THC . THC has been clinically has been shown to be efficacious for neuropathic pain in numerous clinical trials which have been published in reputable peer reviewed journals. Undesired psychoactivity associated with higher doses of the oral formulation has limited its utility for this indication. Relivar aims to deliver the drug in the oral cavity by incorporating it into a tablet that adheres to the gum and releases the drug in the mouth. The benefits are two fold 1 promoting direct absorption through the gums, Relivar can achieve increased bioavailability and reduce the dose required for efficacy ... more details
coord 40.550722 74.4230711 type landmark region US NJ display title PTC Therapeutics is a pharmaceutical company. It is headquartered in South Plainfield , New Jersey . They are the company responsible for the development of PTC124 . ref name pmid17096300 cite journal author Hamed SA title Drug evaluation PTC 124 a potential treatment of cystic fibrosis and Duchenne muscular dystrophy journal IDrugs the investigational drugs journal volume 9 issue 11 pages 783 9 year 2006 pmid 17096300 doi ref As of September 2009, PTC has entered into an agreement with Hoffmann La Roche Roche for the development of orally bioavailable small molecules for central nervous system disease targets. Roche said use of PTC s GEMS technology for the identification of small molecules will enable Roche to address important disease mechanisms that were intractable with conventional approaches. ref http www.firstwordplus.com Fws.do?articleid A2B13ACB78294EB0A27EE127D8339BF3 ref References references Further reading ref name Schneider2009 Cite journal title Firm Aims to Regulate RNA in Rare Diseases url http www.genengnews.com articles chitem.aspx?aid 2869 year 2009 author Schneider, Ilene journal Genetic Engineering & Biotechnology News pages 14 volume 29 issue 8 accessdate 2009 04 25 postscript None ref External links http www.ptcbio.com DEFAULTSORT PTC Therapeutics Category Biotechnology Category Clinical research Category Pharmaceutical industry Category Pharmacology Category Pharmacy Category Companies based in New Jersey pharmacology stub ... more details
Antibe Therapeutics is a Toronto based pharmaceutical research and development company developing inflammation reducing drugs. ref http www.antibe therapeutics.com ref The conceived mechanism of action is to deliver a gaseous mediator , specifically hydrogen sulfide to sites of inflammation or injury within the human body. Hydrogen sulfide enhances the resolution of injury and repair of damage. Antibe was founded by John L. Wallace , co founder of NicOx , the company that was the first to commercialize gaseous mediator technology. Antibe s board of directors includes Louis Ignarro , awarded the 1998 Nobel Prize in Physiology or Medicine for the basic research that underpins gaseous mediator technology, and Dr. Daniel K. Podolsky, Presient of the University of Texas Southwestern . Antibe s products have not yet been approved by the Food and Drug Administration . The lead drug, ATB 346, is a hydrogen sulfide releasing derivative of naproxen, a commonly used non steroidal anti inflammatory drug . Unlike naproxen, ATB 346 does not induce damage in the gastrointestinal tract. Canada company stub References reflist External links http www.nicox.com Official website of NicOx http www.nitricoxideonline.net Nitric Oxide Knowledge Center Website of NicOx Category Pharmaceutical companies of France Category SBF 120 de Nicox fr Nicox http www.ncbi.nlm.nih.gov pmc articles PMC1363746 ... more details
Repros Therapeutics Inc. NASDAQ RPRX , is a United States US based development stage biopharmaceutical company headquartered in The Woodlands, Texas . Founded in 1987 as Zonagen, it is focused on the development of oral small molecule drugs to address major unmet medical needs in male and female health. Joseph S. Podolski ref name Joseph S. Podolski Profile http people.forbes.com profile joseph s podolski 67949 Joseph S. Podolski Profile , Forbes.com ref is the CEO of this company. History The company was organized on August 28, 1987 as Zonagen, to try to develop birth control methods based on modification of the zona pellucida a part of the oocyte . The company bought the rights to the research of Bonnie Dunbar, researcher and professor at the Baylor College of Medicine , and attempted to create a contraceptive vaccine. Zonagen, Inc. was formed in 1987 by Dunbar, Baylor and a group of investors that included Ross Perot and Lloyd Bentsen III, son of a former treasury secretary. The company hoped to market Dunbar s invention as a nonsurgical method of sterilizing dogs and cats. In the meantime, Zonagen would help Dunbar continue the pursuit of her life s work the world s first contraceptive vaccine for humans. Her research, which had been progressing well, ground to a complete halt according to Brian Wallstin of the Houston Press newspaper in his article Biological Disaster. ref Brian Wallstin, http www.houstonpress.com 1998 08 20 news biological disaster Biological Disater , Houston Press Aug 20 1998 ref The company, went public in 1993 with claims that a contraceptive vaccine was imminent. Bonnie Dunbar ended relations with the company and sued them. Zonagen would not develop any commercial product from research relating to the zona pellucida despite naming itself after it. Its next project was to create an adjuvant. These products modify the effects of the active ingredient ... its name to Repros Therapeutics, started to develop other pharmaceutical products for the reproductive ... more details
Orphan date April 2010 Advert date April 2010 Primary sources date April 2010 Cytori Therapeutics , Inc. is a San Diego based regenerative medicine company that develops and manufactures medical devices that enable the therapeutic use of the adult stem cell adult stem and regenerative cells naturally found within adipose tissue adipose fat tissue . Current commercial activities are focused on cosmetic & reconstructive surgery , cell banking and supplying research tools. Company history Cytori began operations under the name MacroPore in 1996, following the invention of a new line of bioresorbable plates and screws for craniofacial surgery based on a polylactic acid polymer technology. By 2000, a commercialization partnership had been formed with Medtronic and two more product lines based on the same technology were developed, one for spinal implants and another adhesion barriers. Between 2000 and 2002, MacroPore began looking at alternative opportunities in regenerative medicine, including a start up stem cell company, StemSource, Inc., which commercialized the processing and banking of adult stem cells originating from adipose tissue. In 2002, MacroPore sold commercialization rights to the craniofacial product line to Medtronic. Later in 2002 MacroPore acquired StemSource and began the development of the Celution System, along with research of clinical applications for the device s stem and regenerative cell output. In 2005, MacroPore changed its name to Cytori and entered into a joint venture with Olympus Corporation. The Olympus Cytori Joint Venture is a collaboration to develop and manufacture the future generations of the Celution System. Core technology the Celution System The Celution System is a medical device that enables beside access to adult adipose derived stem and regenerative cells ADRCs by automating and standardizing the extraction, washing, and concentration of a patient s own ADRCs for present and future clinical use. The Celution System is currently ... more details
wiktionary Lynxlynx A lynx is a type of wild cat. Lynx may also refer to tocright Individuals Emcee Lynx born 1980 , anarchist hip hop artist from the San Francisco Bay Area Lynx Vaughan Gaede 1992 , a member ... Lynx , the name of military versions of the Cessna Skymaster , flown by the Rhodesian Air Force Lynx Aviation disambiguation , the name of more than one airline Westland Lynx helicopter manufactured by AgustaWestland Lynx rocketplane , a rocket powered aircraft under development for a 2010 first flight Maritime HMS Lynx , the name of nine British Royal Navy ships HSC Stena Lynx III , a high speed ferry operated by Stena Line HMS Mosquidobit 1813 Lynx 1812 privateer , a topsail schooner built ... Lynx tall ship , an interpretation of the 1812 privateer schooner, launched in 2001 and based in California USS Lynx , the name of more than three United States Navy ships USS Lynx II SP 730 , later renamed ... Panzer IIL Luchs German for Lynx , a light reconnaissance version of the German Panzer II tank used during World War II Lynx reconnaissance vehicle , a U.S. built military reconnaissance vehicle used by the armed forces of Canada and the Netherlands Lynx Scout Car , a Canadian built version of the World War 2, Daimler Dingo ERC 90 Sagaie ERC 90 Lynx French six wheeled fire support and reconnaissance vehicle Road Leyland Lynx , a model of single decker bus produced by British Leyland in the 1980s and 1990s Lynx snowmobile , a brand of snowmobiles Lynx transportation , a bus system operated by the Central Florida Regional Transportation Authority Mercury Lynx , a model of car Rail GWR no. 2109 Lynx, a South Devon Railway Eagle class steam locomotive Lynx Rapid Transit Services , light rail system in Charlotte, North Carolina Astronomy Lynx constellation , a Northern Hemisphere constellation Lynx Traditional Chinese star name Business Lynx deodorant , a brand of deodorant known as Axe in some markets Lynx , a brand of footwear owned by Colorado Group Limited LYNX Express or simply ... more details
USS Lynx may refer to USS Lynx 1814 , a schooner commissioned in 1815 that disappeared at sea in 1820 USS Lynx SP 2 , a patrol boat in commission from 1917 to 1919 USS Lynx AK 100 , a cargo ship in commission from 1943 to 1945 See also USS Lynx II SP 730 , later renamed USS SP 730 , a patrol boat in commission from 1917 to 1919 Lynx is the kind of cat, and also the name of constellation. Shipindex DEFAULTSORT Lynx Category United States Navy ship names pl USS Lynx ... more details
Ten Royal Navy ships have been named HMS Lynx after the lynx wild cat HMS Lynx 1761 Lynx was a 10 gun sloop launched in 1761 and sold in 1777. HMS Lynx 1777 Lynx was a 16 gun sloop launched in 1777. Converted to a hospital ship in 1780, the ship was sold in 1783. HMS Lynx 1794 Lynx was a 16 gun sloop launched in 1794 and sold in 1813. Lynx was to have been an 18 gun Cruizer class brig sloop Cruizer class brig sloop . Originally ordered in 1812 as HMS Pandora she was renamed Lynx . However construction was canceled in 1818. HMS Lynx 1833 Lynx was a Cherokee class brig sloop Cherokee class brig sloop launched in 1833 and broken up in 1845. HMS Lynx 1854 Lynx was an Arrow class gunvessel Arrow class wooden screw gunvessel launched in 1854 and sold in 1862. HMS Lynx 1868 Lynx was a composite screw gunvessel launched in 1868 and sold in 1888. HMS Lynx 1894 Lynx was a Ferret class destroyer Ferret class destroyer launched in 1894 and sold in 1912. HMS Lynx 1913 Lynx was a Acasta class destroyer Acasta class destroyer launched in 1913 and sunk by a naval mine mine in the Moray Firth in 1915. HMS Lynx F27 Lynx was a Leopard class frigate Type 41 or Leopard class frigate launched in 1955, sold to Bangladesh in 1982 and renamed Abu Bakr . References colledge Shipindex DEFAULTSORT Lynx, Hms Category Royal Navy ship names ... more details
Lynx is originally a Finland Finnish brand of snowmobile s, currently owned by the Canada Canadian company Bombardier Recreational Products . Lynx is a snowmobile brand in Europe and has made many unique inventions in snowmobile technology. Lynx snowmobiles are designed for rough conditions. The newest Lynx snowmobiles are built on the Ski Doo Rev XP platform with minor differences RE X frame , but they use another type of rear suspension called PPS Pauli Piippola Suspension made for rougher conditions. The PPS is tougher, but weighs more than the regular Ski Doo suspension systems. http www.brp.com en Products Lynx Showroom Lynx snowmobiles feature the Bombardier Recreational Products legendary Rotax engine, which is known for its outstanding performance and reliability. http www.brplynx.com about lynx engine technology.html This engine design is also used in Ski Doo brand snowmobiles. The 2011 Lynx lineup features four different categories of snowmobiles which range in performance and function. Current options are Sport, Crossover, Touring, and Utility http www.brplynx.com Category Bombardier Recreational Products Category Snowmobiles Category Tracked vehicles Product stub it Bombardier B 12 no Lynx sn scooter fi Lynx moottorikelkka sv Lynx sn skoter ... more details
Orphan date February 2009 Taxobox name Balkan Lynx status trend status system status ref image regnum Animal ia phylum Chordate Chordata classis Mammal ia ordo Carnivora familia Felidae genus Lynx species Eurasian Lynx L. lynx subspecies L. l. martinoi trinomial Lynxlynx martinoi trinomial authority Miric, 1978 range map range map caption The Balkan LynxLynxlynx martinoi is a subspecies of the Eurasian Lynx in the Lynx genus. ref http www.organismnames.com details.htm?lsid 1604531 ref ref http ... . It is considered to be the largest cat on the continent. The Balkan Lynx has been on the brink ... hostednews afp article ALeqM5gCUfrwwb5eN7JJ0377S HyP WQcA title Poachers put Balkan lynx ... 2 hi europe 6114962.stm title Action urged to save Balkan lynx publisher BBC News accessdate 2009 02 22 date 2006 11 03 ref ref http www.euronatur.org Balkan Lynx Recovery Programme 2.649.0.html ref ... lynx on brink of extinction 999.html ref ref http www.scientificamerican.com blog post.cfm?id last 100 balkan lynx face possible 2009 03 04 ref ref http www.kora.ch news archiv 20100325 2.htm ref ... www.mia.com.mk default.aspx?vId 62364655&lId 2 ref While the Balkan Lynx is listed as a subspecies ..., F. & Breitenmoser, U. 2004 . Status and conservation of the Eurasian lynx in Europe in 2001. Bern KORA. ref References refs External links commonscat Lynxlynx martinoi wikispecies Lynxlynx martinoi https www.kora.ch pdf reports rep19 e countries2.pdf The lynx populations of the Balkan Peninsula. http lynx.uio.no lynx ballynxco 02 status 2 1 situation countries fyr macedonia Pdfs Grubac 2002 Balkan lynx in FRY Macedonia and Montenegro.pdf Contributions on the Balkan lynxLynxlynx martinoi ... rare animals of the balkans 5506 attachment 5 balkan lynx MIRIC, D. 1978 Lynxlynx martinoi ssp ... DwzxAAAAMAAJ&oi fnd&pg PA33&dq 22Lynx lynx martinoi 22&ots IjXZMz8q48&sig b9MNKkpbp6CCFD6hGmNpohVzGr8 ... struga oct 07 proceedings Breitenmoser et al 2008 Strategic planning for Balkan lynx conservation.pdf ... more details
Encyclopedia
top
